CCM
AGIO icon

Cadian Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Cadian Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-75,000
Closed -$3.58M – 27
2019
Q4 		$3.58M Buy
+75,000
New +$2.83M 0.16% 29

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Cadian Capital Management's AGIO Position: Q1 2020 in Review

Cadian Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2020, closing a stake of 75,000 shares — an estimated $3.58M sold.

Cadian Capital Management first reported a position in AGIO in Q4 2019 and held it in 1 quarter. The position peaked at $3.58M in Q4 2019. 197 funds tracked by Wall St. Rank hold AGIO as of Q1 2020.

  • Cadian Capital Management reported no remaining Agios Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Cadian Capital Management sold 75,000 Agios Pharmaceuticals shares in Q1 2020, an estimated $3.58M.
  • Cadian Capital Management first reported a position in Agios Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Cadian Capital Management's Agios Pharmaceuticals position peaked at $3.58M in Q4 2019.
  • 197 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2020.

Based on Cadian Capital Management's 13F filing for Q1 2020, filed 14 May 2020.